Combining the oral RAS inhibitor daraxonrasib with standard chemotherapy shrank tumours in around six in ten previously untreated patients with metastatic pancreatic cancer, according to updated phase I/II results. Median progression-free survival was 12.8 months, well beyond the five to six months typically seen wi…
SL
